A real-world study showed a significant improvement in overall survival (OS) in patients with refractory metastatic colorectal cancer (mCRC) after adding bevacizumab (Avastin) to chemotherapy. Bevacizumab is a VEGF inhibitor that improves results especially in the first and second line of treatment. In study AVF2107, response rates increased from 35% to 45%, progression-free survival (PFS) from 6.2 to 10.6 months, and median OS by nearly a year compared to IFL chemotherapy alone. In second-line treatment, the TML study confirmed that continuation of bevacizumab with chemotherapy extended median OS from 9.8 to 11.2 months. Additional data show a PFS of 9.4 months with bevacizumab versus 8 months without it. Combination with regimens such as FOLFIRI achieved an efficacy of 58.7% and a PFS of 10.3 months. Bevacizumab is given by infusion in combination with chemotherapy based on fluorouracil, oxaliplatin or irinotecan.